Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307514 | 0.78 | RPS6KA2 (0.35) | RPS6KA2HDAC1HDAC2HDAC8RPS6KA3 | |
| SCHEMBL5334047 | 0.78 | RPS6KA2 (0.35) | RPS6KA2HDAC1HDAC2HDAC8RPS6KA3 | |
| SCHEMBL14072191 | 0.76 | RPS6KA3 (0.47) | RPS6KA3 | |
| SCHEMBL30125599 | 0.76 | HDAC1 (0.38) | RPS6KA2HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL8894664 | 0.75 | KDM4E (0.46) | RPS6KA2HDAC1HDAC2HDAC8 | |
| SCHEMBL9386788 | 0.74 | HDAC1 (0.34) | RPS6KA2HDAC1HDAC2HDAC8RPS6KA3 | |
| SCHEMBL14072221 | 0.73 | RPS6KA3 (0.43) | RPS6KA3 | |
| SCHEMBL22363483 | 0.72 | BRD4 (0.37) | RPS6KA2HDAC1HDAC2HDAC8RPS6KA3 | |
| SCHEMBL12894979 | 0.69 | HDAC1 (0.38) | RPS6KA2HDAC1HDAC2HDAC8RPS6KA3 | |
| SCHEMBL25204974 | 0.68 | HDAC1 (0.57) | HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | RPS6KA2 726/4885HDAC1 1906/4885HDAC2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.